Sie suchten nach: mean trough (Englisch - Maltesisch)

trough
hawt

plasma trough
l-inqas

trough fev1 (ml)
l-anqas livell tal-fev1 (ml)

trough concentrations has
konċentrazzjonijiet baxxi

trough and peak fev1:
l-anqas u l-ogħla fev1:

test (trough value)
test (valur minimu)

cmin (trough, g/l)
cmin (minimu, g/l)

trough concentration following once weekly dosing:
l- inqas konċentrazzjoni wara dożaġġ ta ’ darba fil- ġimgħa:

adjusted mean change from baseline in trough fev1 was also evaluated as a secondary endpoint.
il-bidla medja aġġustata mil-linja bażi fl-inqas livell tal-fev1 kienet ukoll evalwata bħala endpoint sekondarju.

(trough level) cmax (mg/dl)/(mg/kg)
(livell minimu) cmax (mg/ dl) / (mg/ kg)

adjusted mean change of trough seated diastolic blood pressure (sedbp) was as follows:
il- bidla medja aġġustata fil- pressjoni tad- demm diastolika meħuda meta pazjent ikun bil- qiegħda (sedbp) kienet kif ġej:

the mean steady-state trough concentration prior to the morning dose was 8.1  5.7 g/ml.
il- konċentrazzjoni minimali medja fissa qabel id-doża ta’ filgħodu kienet ta’ 8.1  5.7 g/ml.

the mean steady-state trough concentration prior to the morning dose was 5.5 ± 4.0 μ g/ ml.
isem u indirizz tad- detentur ta ’ l- awtorizzazzjoni gĦat- tqegĦid fis- suq

the mean serum steady state trough concentrations ranged from 1.6 to 2.1 mcg/ml at weeks 12, 24, and 48.
il-medja tal- konċentrazzjonijiet minimi fis-serum fl-istat fiss varjat minn 1.6 sa 2.1 mcg/ml f’ġimgħat 12, 24, u 48.

trough drug exposures remain at least twenty fold greater than the mean ic95 throughout the dosing interval for both regimens.
espożizzjonijiet ta’ l-aktar konċentrazzjoni baxxa tal-mediċina jibqgħu mill-anqas 20 darba akbar mill-ic95 medju f’kull parti ta’ l-intervall tad-dożaġġ għaż-żewġ korsijiet.

sustained igg trough levels with a mean concentration of 12.53 g/l were thereby achieved throughout the treatment period.
livelli sostnuti l-aktar baxxi ta’ igg b’konċentrazzjonijiet medji ta’ 12.53 g/l kienu b’hekk miksuba matul il-perjodu ta’ kura.

post-dose trough fev1 (least squares mean) at day 1 and week 26 (primary endpoint)
l-anqas fev1 wara l-għoti tad-doża (medja tal-anqas kwadri) fl-1 ġurnata u fis-26 ġimgħa (endpoint primarju)

these ic concentrations may be compared with mean trough concentrations of mavacoxib in plasma in clinical subjects of 0.52 and 1.11 µg/ml, respectively, after the first and fifth doses.
dawn il-konċentrazzjonijiet ic jistgħu jiġu mqabbla mal- medja ta’ konċentrazzjonijiet baxxi fil-plażma ta’ pazjenti kliniċi ta’ 0.52 u 1.11 μg/ml mavacoxib rispettivament, wara l-ewwel u l-ħames doża.

mean peak cetuximab concentrations were 155.8 microgram per ml in week 3 and 151.6 microgram per ml in week 8, whereas the corresponding mean trough concentrations were 41.3 and 55.4 microgram per ml, respectively.
il- medja tal- konċentrazzjonijiet massimi ta ’ cetuximab kienet ta ’ 155. 8 mikrogrammi f’ kull 1 ml f’ ġimgħa 3, u 151. 6 mikrogrammi f’ kull 1 ml f’ ġimgħa 8, filwaqt li l- medja tal- konċentrazzjonijiet l- iktar baxxi kienet ta ’ 41. 3 u 55. 4 mikrogrammi f’ kull 1 ml, rispettivament.

however, approximately 15 % of these patients with hepatic fibrosis had nevirapine trough concentrations above 9,000 ng/ml (2 fold the usual mean trough).
madankollu, madwar 15% ta’ dawn il-pazjenti b’fibrosi epatika kellhom konċentrazzjonijiet l-aktar baxxi ta’ nevirapine ’l fuq minn 9,000 ng/ml (darbtejn l-aktar livell medju baxx).